Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. reports news about its continuous glucose monitoring and glucose biosensing business for people with diabetes. Company updates commonly cover Dexcom G7 clinical evidence, product roadmap activity, U.S. and international revenue trends, margins, guidance, and presentations at diabetes technology and healthcare investor conferences.
Dexcom news also includes corporate governance developments, board appointments, management presentations, and long-term strategy discussions tied to its CGM portfolio, global commercialization, and innovation in metabolic health.
Dexcom, a leader in continuous glucose monitoring (CGM), announced that the Dexcom G6 CGM System is now publicly covered by Alberta Health for children under 18 requiring insulin therapy. This initiative aims to enhance diabetes management for young patients, reducing A1C levels and the likelihood of hypoglycemic incidents. With this expansion, Alberta joins other jurisdictions providing CGM coverage, facilitating access to crucial diabetes technology. The system offers real-time glucose monitoring, alerts, and support for families managing their child's diabetes effectively.
DexCom, Inc. (NASDAQ:DXCM) will release its fourth quarter and full year 2021 financial results after market close on February 10, 2022. A conference call to discuss the results will follow at 4:30 p.m. ET. Investors can access the call via phone or through a webcast on the investor relations website.
Headquartered in location value="LU/us.ca.sandgo"San Diego, California, DexCom focuses on innovative continuous glucose monitoring systems to improve diabetes management.
DexCom, Inc. (Nasdaq: DXCM) anticipates fourth quarter 2021 preliminary revenue of approximately $698 million, a 23% increase year-over-year. U.S. revenue is expected to reach $517 million (up 15%), while international revenue is estimated at $181 million, marking a growth of 54%. Full fiscal 2021 revenue is projected at $2.448 billion, a 27% increase. For 2022, guidance indicates a revenue range of $2.82 billion to $2.94 billion, representing 15-20% growth, driven by increasing CGM adoption.
DexCom, Inc. (NASDAQ:DXCM) announced that CEO Kevin Sayer will present at the 40th annual J.P. Morgan Healthcare Conference on January 10, 2022, starting at approximately 10:30 AM EST. The virtual presentation will be webcasted, and interested parties can access it through the DexCom Investor Relations website. DexCom is a leader in diabetes care technology, focusing on innovative continuous glucose monitoring (CGM) systems to improve diabetes management worldwide.
DexCom, Inc. (NASDAQ:DXCM) announced that Jereme Sylvain, CFO, will present an update at the 33rd Annual Piper Sandler Virtual Healthcare Conference on December 1, 2021, at 2:30 PM (ET). The presentation will be webcasted, and details can be found on the company's investor relations website.
Headquartered in San Diego, California, DexCom specializes in innovative continuous glucose monitoring (CGM) technologies, aiding diabetes management.
Dexcom (NASDAQ:DXCM) is promoting awareness during National Diabetes Awareness Month and World Diabetes Day by encouraging the diabetes community to engage in discussions about healthcare disparities.
Activities include a virtual Congressional testimony featuring Patti LaBelle advocating for better access to diabetes care, along with a campaign led by Nick Jonas on social media to highlight the experiences of people living with diabetes.
The focus is on improving global access to diabetes technology and emphasizing time in range as a key metric for diabetes management.
DexCom reported strong financial results for Q3 2021, with revenue of $650.2 million, a 30% increase from the prior year. U.S. revenue grew by 23%, while international revenues surged 57%. Operating income was $118.3 million, maintaining a healthy margin of 18.2%. DexCom received FDA clearance for two software solutions, enhancing its CGM ecosystem. The company also raised its full-year revenue guidance to approximately $2.425 - 2.450 billion with a projected growth rate of 26-27%.
DexCom (NASDAQ:DXCM) has launched its Time in Range Campaign in the UK, aimed at promoting awareness and adoption of the time-in-range metric in diabetes management. Despite the clinical benefits, a recent UK survey shows fewer than 50% of people with insulin-treated diabetes utilize this metric. Key findings reveal that 83% feel better when spending more time in range, yet 59% do not track it. Additionally, access to continuous glucose monitoring (CGM) technology varies significantly due to the UK's postcode lottery, affecting availability for many.
DexCom (NASDAQ:DXCM) will release its third quarter 2021 financial results after market close on October 28, 2021. A conference call to discuss the results will take place at 4:30 p.m. ET on the same day, with a webcast available on the DexCom investor relations website. Investors can join the call by dialing (800) 446-1671 or (847) 413-3362 for international calls, using confirmation number '49591484'. DexCom is a leader in diabetes management, providing innovative continuous glucose monitoring systems.
Dexcom (NASDAQ: DXCM) announces that the Dexcom G6 Continuous Glucose Monitoring (CGM) System is now eligible for provincial coverage in Manitoba for individuals with type 1 diabetes aged 25 and under. This move expands access to CGM technology, joining other provinces like British Columbia and Quebec that already provide coverage. The Dexcom G6 system allows users to monitor glucose levels continuously, reducing reliance on fingerstick tests. The initiative aims to improve diabetes management and health outcomes for young individuals with diabetes in Manitoba.